PASURTA
ERENUMAB
What it does
Erenumab is a medication used to help prevent migraines.
Commonly used for: migraines, migraine prevention
Read more in plain English ↓Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.
Ask about this medicine
Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.
Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.
Sourcing - Kenya onlyRegistration & product details
Source: Food and Drugs Authority · fetched 2026-04-18 08:33:04 · updated 2026-09-18 04:00:07
About this medicine
Erenumab is a medication used to help prevent migraines.
What it treats
- migraines
- migraine prevention
How it works
Erenumab works by blocking a specific protein involved in the development of migraines, helping to reduce the frequency and severity of migraine attacks.
Who it's for
This medication is for adults who experience frequent migraines and want to reduce the number of migraine days.
AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.
Clinical monograph: Erenumab
BNF-referencedErenumab is a human monoclonal antibody designed for the prophylaxis of migraine. It acts by binding to the calcitonin gene-related peptide (CGRP) receptor, thus inhibiting the function of CGRP, a key molecule involved in migraine pathophysiology. This drug is indicated for patients experiencing frequent migraine attacks and is typically initiated by a specialist.
Indications
- Prophylaxis of migraine in adults with a history of frequent migraine attacks
Dosage
Children: Refer to the BNF for Children for pediatric dosing information.
Adults: Initially, 100 mg subcutaneously every 12 weeks; may increase to 300 mg every 12 weeks if necessary, with assessment for dose escalation within the first 12 weeks.
Mechanism of action
Erenumab binds specifically to the calcitonin gene-related peptide (CGRP) receptor, inhibiting its activity. This blockade prevents the physiological effects of CGRP, which include vasodilation and inflammation associated with migraine attacks.
Pharmacodynamics
By inhibiting the action of CGRP, Erenumab reduces the frequency and severity of migraine attacks. Clinical studies have demonstrated its efficacy in decreasing the number of migraine days experienced by patients, with a favorable safety profile.
Pharmacokinetics
Erenumab is administered via subcutaneous injection and has a half-life that allows for dosing every 12 weeks. It demonstrates linear pharmacokinetics with minimal variability among patients. The drug is primarily eliminated through the reticuloendothelial system, and its clearance may be influenced by factors such as body weight.
Contra-indications
- Hypersensitivity to the active substance or to any of the excipients
- Severe hepatic impairment
Adverse effects
- Fatigue
- Hypersensitivity reactions
- Nasopharyngitis
Interactions
- No significant drug interactions documented; however, caution is advised when used with other medications affecting migraine management
Precautions
- Use with caution in patients with mild to moderate hepatic impairment
- Monitor patients for signs of hypersensitivity reactions
- Review treatment after 6 months of therapy
Pregnancy
Avoid use during pregnancy due to limited information available regarding safety.
Breast-feeding
Amount too small to be harmful; use with caution during breastfeeding.
Storage
Store in a refrigerator at 2-8°C, protect from light.
Formulations
- Solution for infusion
AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.
This drug in other countries
The same active ingredient registered across other registries we cover - including different brands.